TransMedics Group, Inc. $70 Million Follow-On Offering

Davis Polk advised the representatives of the underwriters in connection with the $70 million follow-on public offering of 5,000,000 shares of common stock of TransMedics Group, Inc. TransMedics Group, Inc. is listed on the Nasdaq Global Market under the symbol “TMDX.”

TransMedics Group, Inc. is a commercial-stage medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure.

The Davis Polk capital markets team included partner Richard D. Truesdell Jr. and associates Chris Van Buren and Ernesto Talamás Velázquez. Partner David R. Bauer and associates Jesse L. Hallock and Chelsea Renter provided intellectual property advice. The tax team included partner Mario J. Verdolini and associate Danielle Rapaccioli. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.